Orteq is headquartered in London, UK and has offices in Utrecht, The Netherlands and New York, USA. It was established to develop and commercialize joint preserving technologies using its proprietary polymer technology platform and its single surgery Autologous Chondrocyte Implantation (ACI) technology.
Orteq received its CE Mark renewal for ACTIfit on July 17, 2019 and is now available in over 30 countries.
On February 19, 2020 Orteq received approval from KFDA to commercialize ACTIfit in South Korea.
On April 1, 2020 Orteq received US FDA Breakthrough Designation for ACTIfit.
For additional information about sales partners please contact email@example.com
Orteq has identified other promising sports medicine applications for its polymer platform. This platform development will continue now that we can safely broaden our focus past the largest meniscus opportunity given ACTIfit’s emerging acceptance in the surgical community.
ACTIfit was developed in conjunction with some of the world’s leading orthopedic sports/medicine surgeons. Made from our unique polymer, ACTIfit is the first biodegradable, synthetic scaffold, designed to help repair meniscal tears. Actifit is safe, tough, and extremely easy to handle in surgery.
A meniscus tear is normally treated by the removal of the torn or damaged tissue via a partial meniscectomy. This type of procedure can be effective in the short term but often only gives temporary pain relief. In many cases the pain returns in time due to the loss of meniscal tissue and the cushioning function provided by a healthy meniscus. Over a longer period, there is overwhelming evidence that degenerative changes occur, which, if left untreated, can lead to articular cartilage damage, the onset of osteoarthritis, and eventually a total knee replacement.